Table 4.

Randomized Controlled Trials of Brain-Derived Neurotrophic Factor (BDNF) Augmented Exposure-based Therapies

Study	Diagnosis	Sample	Type of Therapy	# of Sessions	Expedited Tx. Gains	Outcome at Post-Tx.	Tx. Outcome at Follow-up Assessment
Kobayashi et al. [101]	PD	42 adults	Exposure-based group CBT	10 (60min)	Not assessed	Treatment responders exhibited a higher level of BDNF serum at BL relative to poor responders	Not assessed.
Fullana et al. [102]	OCD	98 adults who were SSRI partial or non-responders	Exposure-based CBT	20 sessions (45 min)	Not assessed	BDNF Val66Met group exhibited lower treatment response on Y-BOCS (36%) relative to non-carriers (60%)	Not assessed.
Felmingham et al. [103]	PTSD	55 adults	Exposure-based CBT	8 sessions	Not assessed.	BDNF MET group exhibited lower treatment response (40% reduction) relative to non-BDNF Met Group (62% reduction). Significant difference in CAPS scores at post-tx, favoring non-BDNF group	Not assessed.

Note: PD = Panic Disorder; CBT = Cognitive Behavioral Therapy; Panic Disorder Severity Scale; SSRI = Selective Serotonin Reuptake Inhibitors; Y-BOCS = Yale-Brown Obsessive Compulsive Scale; CAPS = Clinician Administered PTSD Scale.